Radiographic review of Noxopharm’s DARRT-1 Clinical Study Returns Remarkable Outcomes

April 30, 2020 01:04 PM AEST | By Team Kalkine Media

Google News:

Recent News

Skywork-Reward-V2: Leading the New Milestone for Open-Source Reward Mo...

13th World Peace Forum held in Beijing, calls for shared responsibilit...

Enhancing Capacity and Logistics Flow, Minister Al-Jasser Lays Foundat...

Dalai Lama’s 90th: A Global Celebration of Compassion, Peace, and Wisd...

In a considerable development, biotech player Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study. The Company reported that the review demonstrates a significant benefit from a combination of low-dose radiotherapy and Veyonda®.

Additionally, the Company highlighted:

Review providing further evidence of Veyonda®’s anti-cancer effect in patients with end-stage prostate cancer.
4/15 patients witnessed an abscopal response following DARRT, which is a remarkable result.
In Company’s knowledge, this is first time that anyone has been able to attain a meaningful abscopal response rate in prostate cancer.

Post the key update, NOX stock inched higher by ~2.4 per cent, trading at $0.210 as at 12:07 PM AEST on 30^th April 2020.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.